DUBLIN–(BUSINESS WIRE)–The “Pain
Therapeutics – Drugs, Markets and Companies” report from Jain
PharmaBiotech has been added to ResearchAndMarkets.com’s
offering.
This report describes the latest concepts of pathomechanisms of pain as
a basis for management and development of new pharmacotherapies for
pain. Major segments of the pain market are arthritis, neuropathic pain
and cancer pain. Because pain is a subjective sensation, it is difficult
to evaluate objectively in clinical trials. Various tools for pain
measurement are described, including brain imaging.
Most of the currently used analgesic drugs fall into the categories of
opioids and nonsteroidal anti-inflammatory drugs such as COX-2
inhibitors. Non-opioid analgesics include ketamine, a
N-methyl-D-aspartate receptor antagonist. Adjuvant analgesics include
antidepressants and antiepileptic drugs used for the treatment of
neuropathic pain. Management of pain is multidisciplinary and includes
both pharmacological and non-pharmacological methods such as
acupuncture, transcutaneous electrical nerve stimulation and surgery.
Various pain syndromes require different approaches in management, for
example, the main category of drugs for migraine are triptans such as
sumatriptan.
Drug delivery is an important consideration in pain treatment.
Controlled release preparations provide a steady delivery of analgesics.
Well-known non-injection methods such as transdermal, pulmonary and
intranasal application have been used. Topical analgesics and local
anesthetics are also available. Devices such as implanted pumps are used
for delivery of drugs such as opioids intrathecally (introduction into
spinal subarachnoid space by lumbar puncture) in patients with cancer
pain.
The wide variety of drugs in development includes opioid receptor
ligands, bradykinin antagonists, mPGES-1 inhibitors, glutamate receptor
antagonists, substance P and neurokinin receptor antagonists,
norepinephrine transporter inhibitors, P2X2 neuron receptor antagonists
and nitric oxide-based analgesics.
A number of cannabinoids are also in development for pain. Fish-derived
tetrodotoxin was initially focused on indication of opiate addiction
withdrawal but is found to have an analgesic action as well. Cone shells
contain therapeutically useful peptides including the conotoxins, and
one such peptide, ziconotide, has been approved. Various cell and gene
therapies are also being developed for the management of pain.
Advances in molecular and biological techniques are markedly advancing
our understanding of pain. Understanding the pathophysiology of pain is
an important factor in discovery of rational therapies for pain.
Advances in pharmacogenomics and pharmacogenetics are enabling the
development of personalized approaches to the management of pain.
Over 500 companies have been identified to be involved in developing or
marketing pain therapeutics and 173 of these are profiled in the report
along with 156 collaborations. These are a mix of pharmaceutical
companies and biotechnology companies.
The worldwide analgesic markets were analyzed for the year 2018 and
projected to 2028. Calculations are based on the epidemiology of various
painful conditions and the development of analgesic drugs and devices.
Unfulfilled needs for analgesics are identified and strategies are
outlined to develop markets for analgesic drugs. The report is
supplemented with 76 tables, 23 figures, and 600 selected references to
the literature.
Key Topics Covered:
Executive Summary
1. Basic Aspects of Pain
2. Assessment of Pain and Analgesics
3. Pharmacotherapy of Pain
4. Management of Pain
5. Drug Delivery for Pain
6. Drug Development for Pain
7. Safety, Regulatory and Legal issues of pain management
8. Pain Markets
9. Future of Pain Therapeutics
10. Companies Involved in Pain Therapeutics
11. References
For more information about this report visit https://www.researchandmarkets.com/research/bmdn8c/world_pain?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Analgesics